Kolkata launches mobile‑app suite to expand breast cancer outreach, early detection and treatment support

Spread the Message

Read Time:6 Minute, 21 Second

In a bid to tackle India’s rising breast cancer burden, the Institute of Breast Disease (IBD), Kolkata, has rolled out two mobile applications—ME App and ChemoCare—aimed at strengthening early detection, self‑awareness and chemotherapy adherence among women across urban and rural West Bengal. The apps were formally inaugurated in Kolkata by Dr Swapan Saren, Director of Health Services, West Bengal, alongside senior state health and education officials, underscoring the state government’s push to integrate digital tools into routine breast‑health care.

Key features of the new apps

ME App: self‑examination and symptom tracking

The ME App is designed to encourage regular breast self‑examination (BSE) and daily monitoring of breast symptoms. It offers:

Alert‑based reminders for self‑exams and symptom checks.
Step‑by‑step guidance on how to perform a structured self‑examination.
A mastalgia (breast pain) tracking system built around the Kolkata Breast Pain Chart, an in‑house tool developed at IBD Kolkata to standardise how women report breast pain patterns.

Users can log changes such as lumps, nipple discharge, skin changes, or persistent pain, which the app converts into structured, shareable data that can be shown to clinicians during consultations. The beta version of ME App went live on 8 January 2026, with plans to expand language and feature support in subsequent updates.

ChemoCare: digital companion during chemotherapy

The second app, ChemoCare, functions as a digital companion for patients undergoing chemotherapy. It helps users:

Track common side effects such as nausea, fatigue, hair loss, mouth sores and mood changes.
Monitor treatment schedules, including drug cycles and supportive medications.
Maintain a symptom diary that can be shared with oncologists to adjust doses or supportive care.

By simplifying day‑to‑day tracking, the app aims to reduce treatment abandonment, a well‑documented problem in Indian cancer care where financial strain, side‑effect burden and lack of psychosocial support lead some patients to stop therapy prematurely.

Broader digital ecosystem: AI‑driven screening with ASHA workers

Beyond the patient‑facing apps, IBD Kolkata is collaborating with the West Bengal Health Department on an AI‑powered breast‑cancer screening and patient‑tracking platform for ASHA workers. Under this initiative:

ASHA workers visit households and collect basic breast‑health data using a simple questionnaire (for example, presence of a lump, nipple discharge, or skin changes).
The app then uses an AI‑based protocol to classify women as high‑risk or low‑risk, guiding referrals for ultrasound or clinical examination at district‑level facilities.
Suspected cases are tracked in real time, with follow‑up reminders and outcome monitoring across the hospital network.

This model aims to decentralise screening, reducing the need for women to travel long distances to big city hospitals and lowering out‑of‑pocket costs at advanced stages.

Why this matters: India’s breast cancer burden

Breast cancer is already the most common cancer among women in India, and recent projections from the Indian Council of Medical Research (ICMR)–National Centre for Disease Informatics and Research (NCDIR) suggest the incidence is rising by about 5.6% per year, adding roughly 50,000 new cases annually. In 2022, breast cancer accounted for the highest number of new cancer cases among Indian women, ahead of cervical, ovarian and endometrial cancers.

Experts point out that late diagnosis and incomplete treatment remain major drivers of poor outcomes. Many women first present with advanced‑stage disease, where curative options are limited and costs are higher. Digital tools like ME App and ChemoCare, if scaled, could help shift the curve toward earlier detection and better treatment adherence.

Expert perspectives: cautious optimism

Dr Soumen Das, Founder Director of IBD Kolkata, described the apps as part of the institute’s long‑term vision of “integrating technology with medicine”. He highlighted that late diagnosis and mid‑treatment dropout are two of the biggest barriers to effective cancer care, and that digital nudges and symptom tracking can help mitigate these gaps.

Oncologists not directly involved in the project also see potential. Dr Rosina Ahmed, a medical oncologist at Tata Medical Center, Kolkata, who works extensively with breast‑cancer patients, told a health‑policy outlet that reminders, symptom logs and easy communication channels can improve patient–clinician dialogue and allow earlier intervention for severe side effects. However, she emphasised that apps are adjuncts, not substitutes, for clinical evaluation and that any concerning symptom should prompt an in‑person consultation.

Public‑health specialists note that AI‑driven screening tools for ASHA workers could be transformative in rural and semi‑urban areas, where awareness is high but access to specialists is low. A 2025 survey cited by state health officials found that about 84% of rural respondents knew about breast cancer, yet many still delay or avoid care due to stigma, distance and cost.

Implications for women and families

For individual users, the ME App and ChemoCare can:

Normalise breast self‑examination as a routine habit, similar to checking blood pressure or weight.
Provide a private, low‑threshold way to record symptoms and share them with doctors, especially for women who may feel uncomfortable discussing breast issues openly.
Help chemotherapy patients feel more in control of their side effects, potentially improving quality of life and treatment completion rates.

At the system level, the AI‑driven ASHA app could:

Create a real‑time breast‑cancer surveillance layer across West Bengal, flagging clusters or high‑risk areas for targeted campaigns.
Reduce unnecessary referrals by triaging women into risk categories before they undergo imaging.

However, experts caution that equity of access remains a challenge. Not all women own smartphones, and digital literacy, especially among older and rural populations, may limit uptake unless the apps are paired with offline counselling and community‑based education.

Limitations and balanced considerations

While promising, these digital tools have limitations:

Apps cannot replace clinical examination or imaging. A negative self‑exam or reassuring symptom log does not rule out breast cancer.
Data privacy and security are critical, particularly for sensitive health information; users should check the apps’ privacy policies and ensure they are downloaded from official stores.
AI‑based risk categorisation is only as good as the data it is trained on; false reassurance or over‑referral could occur if algorithms are not regularly validated in Indian populations.

Moreover, digital solutions alone cannot address structural barriers such as treatment costs, transport, and workforce shortages. They work best when embedded within strengthened primary‑care and oncology networks.

What this means for everyday health decisions

For women in India, especially those aged 40–50, when breast cancer incidence is rising, these developments suggest several practical steps:

Make self‑examination routine, using an app or calendar reminders if that helps consistency.
Report any persistent lump, nipple change, skin dimpling or unusual pain to a doctor promptly, even if an app’s symptom log seems “mild”.
If undergoing chemotherapy, consider using a treatment‑tracking app to log side effects and share the record with the oncology team at each visit.

Health‑system planners may look to the Kolkata model as a template for state‑level digital‑health pilots, combining frontline workers, AI triage and patient‑facing apps to close gaps in early detection and continuity of care.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health‑related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.